ReviewMethods (San Diego, Calif.)2016
Oligonucleotide aptamers: A next-generation technology for the capture and detection of circulating tumor cells.
Review in Methods (San Diego, Calif.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Circulating Tumor Cells Adhesion: Application in Biosensors.Biosensors · 2023Review
- Functionalized liposomes for targeted breast cancer drug delivery.Bioactive materials · 2023Review
- Recent progress in aptamer-based microfluidics for the detection of circulating tumor cells and extracellular vesicles.Journal of pharmaceutical analysis · 2023Review
- Circulating tumor cell isolation for cancer diagnosis and prognosis.EBioMedicine · 2022Review
- Detection of circulating tumor cells: opportunities and challenges.Biomarker research · 2022Review
- Aptamer Conjugated Indium Phosphide Quantum Dots with a Zinc Sulphide Shell as Photoluminescent Labels forNanomaterials (Basel, Switzerland) · 2021Article
- Recent Development of Nanomaterials-Based Cytosensors for the Detection of Circulating Tumor Cells.Biosensors · 2021Review
- Capture and selective release of multiple types of circulating tumor cells using smart DNAzyme probes.Chemical science · 2020Article
- Biostable Double-Strand Circular Aptamers Conjugated Onto Dendrimers for Specific Capture and Inhibition of Circulating Leukemia Cells.OncoTargets and therapy · 2020Article
- Aptamers as Diagnostic Tools in Cancer.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Combined use of EpCAM and FRα enables the high-efficiency capture of circulating tumor cells in non-small cell lung cancer.Scientific reports · 2018Article
- Lab-on-a-Chip Platforms for Detection of Cardiovascular Disease and Cancer Biomarkers.Sensors (Basel, Switzerland) · 2017Review
- Development of a DNA Aptamer for Screening Neisseria meningitidis Serogroup B by Cell SELEXIranian biomedical journal · 2017Article
- Rapid and Sensitive Detection of Breast Cancer Cells in Patient Blood with Nuclease-Activated Probe Technology.Molecular therapy. Nucleic acids · 2017Article
- Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells.Chemical Society reviews · 2017Review
- Review
- Characterization of the specific interaction between the DNA aptamer sgc8c and protein tyrosine kinase-7 receptors at the surface of T-cells by biosensing AFM.Analytical and bioanalytical chemistry · 2017Article
- High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency.Scientific reports · 2016Article
- Clinical and biological significance of circulating tumor cells in cancer.Molecular oncology · 2016Review
- Circulating tumor cell isolation, culture, and downstream molecular analysis.Biotechnology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A critical challenge for treating cancer is the early identification of those patients who are at greatest risk of developing metastatic disease. The number of circulating tumor cells (CTCs) in cancer patients has recently been shown to be a valuable (and non-invasively accessible) diagnostic indicator of the state of metastatic disease. CTCs are rare cancer cells found in the blood circulation of cancer patients believed to provide a means of diagnosing the likelihood for metastatic spread and assessing response to therapy in advanced, as well as early stage disease settings. Numerous technical efforts have been made to reliably detect and quantify CTCs, but the development of a universal assay has proven quite difficult. Notable challenges for developing a broadly useful CTC-based diagnostic assay are the development of easy-to-operate methods that (1) are sufficiently sensitive to reliably detect the small number of CTCs that are present in the circulation and (2) can capture the molecular heterogeneity of tumor cells. In this review, we describe recent progress towards the application of synthetic oligonucleotide aptamers as promising, novel, robust tools for the isolation and detection of CTCs. Advantages and challenges of the aptamer approach are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.